
	Where results make sense

Topic: ImClone Systems

Related Topics

Martha Stewart

NASDAQ

Peregrine Systems

Computer Associates

Merrill Lynch

WorldCom

South Sea Bubble

Freddie Mac

Lucent Technologies

Corporate abuse

Tyco International

Sunoco

Corporate accounting scandals

Qwest Communications

Xerox

	ImClone Systems Incorporated (Site not responding. Last check: 2007-10-12)
		ImClone Systems Incorporated (Nasdaq: IMCL) is a biopharmaceutical company dedicated to developing breakthrough biologic medicines in the area of oncology.
		ImClone Systems’ goal is to become a fully-integrated biopharmaceutical company that has the capability and resources to take its novel pipeline compounds and develop them from the research and development stage through to commercial manufacture, marketing and sales.
		ImClone Systems operates in three locations - its corporate and scientific headquarters at 180 Varick Street in New York City, which houses the Company's research and executive offices, its chemistry facility in Brooklyn, New York and its campus in Branchburg, New Jersey.
	jobs.adsumo.com /jobseekerx/ViewCompanyProfile.asp?CompanyProfileID=39 (255 words)

	Imclone Systems Incorporated and LonBiologics
		ImClone Systems' IMC-C225 is a monoclonal antibody that is designed to target and block the Epidermal Growth Factor receptor (EGFr), which is associated with tumor cell growth and repair in a number of solid tumors.
		ImClone Systems is also conducting a Phase II study evaluating IMC-C225 in combination with cisplatin in patients with refractory advanced squamous cell head and neck carcinoma and a Phase II study evaluating IMC-C225 in combination with gemcitabine in patients with pancreatic carcinoma.
		ImClone Systems Incorporated is advancing oncology care by developing a portfolio of targeted biologic treatments, designed to address the medical needs of patients with a variety of cancers.
	www.lonza.com /group/en/company/news/archive/news2000/imclone.html (843 words)

	ImClone Systems - Wikipedia, the free encyclopedia
		ImClone Systems Incorporated (NASDAQ: IMCL) is a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology.
		This was the year that ImClone CEO Waksal first forged the signature of the company's general counsel John Landes (one of the three original employees of the company) for financial gain.
		ImClone Systems Incorporated Announces Decision by The FDA Not To Accept For Filing The ERBITUX Biologics License Application.
	en.wikipedia.org /wiki/ImClone_Systems (989 words)

	News: ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement. Genetic Engineering News - Biotechnology ...
		ImClone Systems Incorporated (NASDAQ: IMCL) and Merck KGaA, Darmstadt, Germany, announced today that they have entered into agreements amending and supplementing the 1998 development and license agreement covering ERBITUX(R) and certain other work in the field of EGFR-targeted antibodies.
		ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.
		ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.
	www.genengnews.com /news/bnitem.aspx?name=3453673 (539 words)

	CNN.com - Icahn's ImClone interest - Feb. 15, 2002
		ImClone adopted a shareholder rights plan Friday after filings to the Federal Trade Commission and the Justice Department from Icahn's company seeking clearance to acquire up to $500 million in ImClone common stock.
		ImClone is also the subject of informal investigations from the Securities and Exchange, the Justice Department and the U.S. House Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce.
		Bristol-Myers will be joining ImClone at the FDA meeting, despite the biotech rejecting Bristol-Myers' demand to restructure their partnership.
	cnnstudentnews.cnn.com /2002/BUSINESS/02/15/imclone (929 words)

	Pharmaceutical Technology - Branchburg Biopharmaceutical Plant owned by ImClone Systems Incorporated, USA
		ImClone Systems Incorporated was founded in 1986 and opened its first research laboratories in New York.
		ImClone and Bristol-Myers Squibb have also filed a supplemental Biologics License Application (sBLA) with the FDA in the third quarter of 2005 to seek approval of Erbitux for use as a single agent and in combination with radiation in SCCHN.
		Imclone Systems Incorporated's biopharmaceutical manufacturing facility in Branchburg, New Jersey, was approved by the FDA in July 2002 to produce investigational quantities of Erbitux (IMC-C225).
	www.pharmaceutical-technology.com /projects/branchburg (928 words)

	USATODAY.com - Rival deals ImClone new blow after suit (Site not responding. Last check: 2007-10-12)
		ImClone Systems (IMCL) is under pressure from biotech rival Amgen following a court ruling Monday in which ImClone lost a patent dispute covering use of its sole product, cancer drug Erbitux.
		ImClone shares fell 4.5% Tuesday on news of the court ruling, released late Monday.
		ImClone has said it intends to appeal the court ruling, which said three Israeli scientists are the patent's inventors — not the seven people listed.
	www.usatoday.com /money/industries/health/drugs/2006-09-19-imclone_x.htm?csp=34 (489 words)

	ImClone Systems Incorporated Announces Decision by The FDA Not To Accept For Filing The ERBITUX Biologics License ...
		ImClone Systems Incorporated (Nasdaq: IMCL) announced today that the U.S. Food and Drug Administration (FDA) has advised the Company that at this time it is not accepting for filing in its current form the Company's rolling Biologics License Application (BLA) for ERBITUX(TM).
		ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments, designed to address the medical needs of patients with a variety of cancers.
		ImClone Systems is headquartered in New York with manufacturing facilities in Somerville, New Jersey.
	www.findarticles.com /cf_dls/m0EIN/2001_Dec_28/81172317/p1/article.jhtml (678 words)

	USATODAY.com - ImClone goes up against patent dispute (Site not responding. Last check: 2007-10-12)
		More bad news could be looming for ImClone Systems (IMCL), the biotech maker at the heart of the Martha Stewart stock scandal.
		ImClone and Aventis say Schlessinger and his colleagues had already conceived of the patent claims before that conversation and that he simply asked the Sela colleague to test the idea in routine experiments.
		ImClone, in a court filing, said that three of the seven authors on the 866 patent should be deleted because they had nothing to do with its claims.
	www.usatoday.com /money/industries/health/drugs/2006-09-14-imclone-usat_x.htm (1233 words)

	Drug Stocks: Biotechnology & Pharmaceutical Sectors - Discussion: IMCL : ImClone Systems
		ImClone officials, principally Dr. Waksal, had repeatedly reassured investors that the drug was on track at the FDA.
		In May 2001, ImClone was the center of attention at the annual meeting of the American Society of Clinical Oncology.
		Doctors there were encouraged by ImClone's data from a small clinical trial showing that Erbitux, combined with chemotherapy, reduced the size of certain human cancer tumors by at least 50%.
	www.suite101.com /discussion.cfm/investing/21616/655242 (2971 words)

	FOXNews.com - ImClone Ex-CEO Arrested on Insider Trading Charges - Business And Money \| Business News \| Financial News
		ImClone, which is developing an experimental cancer drug, Erbitux, learned before the general public that the U.S. Food and Drug Administration would not accept the company's marketing application for its drug, the complaint said - information that when made public sent the company's shares plunging.
		Waksal, 54, who was replaced as ImClone CEO by his brother, Harlan, on May 22, was arraigned in New York federal court on Wednesday on two counts of conspiracy to commit securities fraud, six counts of insider trading and one perjury charge.
		ImClone is in the midst of a grueling week of questions from shareholders and lawmakers about whether company executives defrauded investors while enriching themselves and those close to them.
	www.foxnews.com /story/0,2933,55101,00.html (1007 words)

	lexisONE(R) ImClone Systems Agrees To Settle 2 Suits (Site not responding. Last check: 2007-10-12)
		ImClone, which was at the center of a scandal that sent company founder Sam Waksal and his friend Martha Stewart to jail, said it will pay $75 million in cash to settle a class-action lawsuit that alleges the company violated securities laws by misleading investors on the approval status of Erbitux.
		ImClone also settled shareholder-derivative litigation and will get a $8.5 million payment from its insurance carriers to pay the class-action settlement, it said.
		Stewart was sentenced to jail for five months for lying to prosecutors investigating allegations that she knew of Erbitux's imminent rejection by the FDA when she sold ImClone shares in December 2001.
	www.lexisone.com /news/ap/ap012405b.html (269 words)

	ABC News: ImClone Systems Mulls Selling, Merging Co. (Site not responding. Last check: 2007-10-12)
		ImClone shares rose $1.37, or 4 percent, to $35.43 in early trading on the Nasdaq after the news of its possible sale.
		ImClone said Fischer, a member of its board since 2003, will replace Philip Frost, who was named interim CEO in November.
		ImClone said it does not plan to disclose further information about the strategic review until the process is completed or it reaches an agreement.
	abcnews.go.com /Business/wireStory?id=1535418 (401 words)

	BIO.COM: Biotechnology Pharmaceutical Market, Stocks, Finance, Merger, Acquisition - Biotech, Pharma, Biomedical (Site not responding. Last check: 2007-10-12)
		ImClone Systems reported that the antibodies, IMC-11F8 and IMC-1121B, both of which target growth factor receptors, are being evaluated for their potential as cancer therapeutics.
		As reported by ImClone Systems, inhibition of the function of this receptor with IMC-1121B blocks angiogenesis (the growth of new blood vessels), thereby limiting nutrient supply to the tumor and causing tumor cell death in preclinical models.
		ImClone Systems announced in a company press release dated January 5, 2005 that it has entered IMC-1121B into Phase I development in the United States.
	www.bio.com /industryanalysis/industryanalysis_news.jhtml?cid=7100038 (787 words)

	ImClone Systems Gearing Up For Erbitux Launch
		BOSTON (Dow Jones)--While ImClone Systems Inc. (NasdaqNM:IMCL - News) is gearing up for the launch of its colon cancer drug Erbitux, it also has a host of other product applications in the pipeline, its chief executive said Wednesday.
		He said ImClone, which won Food and Drug Administration's (News - Websites) approval on its application for treatment of its colon cancer drug Erbitux on Feb. 12, is working toward other applications for Erbitux such as for head and neck, lung, pancreatic cancers.
		ImClone's Erbitux has been at the center of an insider-trading scandal that put the company's founder in jail and led to the trial and conviction of Martha Stewart (News).
	www.omniomix.com /inthenews.php?id=20195 (280 words)

	Case - Imclone Systems, Inc. - Kaplan Fox
		This is a securities class action on behalf of purchasers of the common stock of ImClone Systems, Inc. (“Imclone”) (NASDAQ: IMCL) between May 12, 2001 and January 18, 2002, inclusive (the “Class Period”).
		The complaint alleges that it was false and misleading for defendants to represent that ImClone had presented the evidence necessary to allow the FDA to accept its Erbitux application when they knew the application did not comply with the stated expectations of the FDA.
		ImClone shocked the market when, on December 28, 2001, it announced that the FDA had declined to accept its Fast-Track application to market Erbitux.
	www.kaplanfox.com /case.php?&id=40 (214 words)

	Biotech News: Morning Alert for Imclone Systems Inc
		ImClone Systems hopes to put all the drama behind it and just get on with the business of making drugs.
		ImClone's future with the drug became uncertain in 2006, however, when a federal court ruled that three scientists from Israeli drug firm Yeda were the real patent-holders of ERBITUX.
		ImClone had licensed the drug from Sanofi-Aventis, who had claimed ownership of the key patent related to the drug.
	news.tradingcharts.com /futures/3/0/85674903.html (967 words)

	Bristol-Myers Squibb - Newsroom - Press Release - ImClone Systems And Bristol-Myers Squibb Provide Erbitux® ...
		ImClone Systems and Bristol-Myers Squibb will initiate a randomized Phase III clinical trial (IMCL-0452) evaluating chemotherapy alone, either with docetaxel or pemetrexed, or the same chemotherapy in combination with Erbitux in 800 patients with second-line non-small cell lung cancer.
		ImClone Systems and Bristol-Myers Squibb also plan to initiate two supportive first-line randomized clinical studies using chemotherapy regimens more commonly used by U.S. physicians, including a taxane with platinum-based chemotherapy and gemcitabine with platinum-based chemotherapy, plus or minus Erbitux.
		Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux®; is a registered trademark of ImClone Systems Incorporated.
	www.bms.com /news/press/data/fg_press_release_5050.html (1322 words)

	ImClone Systems News
		ImClone Systems Incorporated and Bristol-Myers Squibb Company have recently announced the results of two randomized Phase III trials of ERBITUX in metastatic colorectal cancer patients.
		ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced results from two randomized Phase III trials of Erbitux in patients with metastatic colorectal cancer.
		Saying ImClone Systems Inc. lacks rights to a patent used for its blockbuster Erbitux drug, the licensing arm of an Israeli research institution has asked a judge to award it restitution and order ImClone to...
	www.topix.net /com/imcl (701 words)

	The Trials of ImClone
		What's more, in April, ImClone was warned by Nasdaq that its stock could be delisted if its 10-K wasn't filed by June 23, potentially triggering the collapse of all that ImClone's staff had worked so hard to build.
		In the first quarter of this year, ImClone announced its first significant profits; in an industry in which only some 10 or 15 biotechs are profitable, it was a stunning achievement -- especially for a company that had been nearly written off as dead.
		While ImClone flew high on its stellar scientific credentials, Lynch discovered that the company's back-office functions -- finance, legal, and general management -- were in disarray.
	www.fastcompany.com /magazine/86/imclone.html (909 words)

	ImClone Systems CEO Steps Down
		ImClone Systems (IMCL:Nasdaq - news - commentary - research - analysis) said late Wednesday that CEO Sam Waksal has resigned from the troubled biotech company.
		In March, a congressional committee investigating ImClone asked Sam Waksal to provide detailed financial records and other information about his, and his family's, trading in the company's stock.
		ImClone has lost 85% of its value since trading around $70 in the beginning of December.
	www.thestreet.com /tech/adamfeuerstein/10023800.html (568 words)

	Drug Stocks: Biotechnology & Pharmaceutical Sectors - Discussion: IMCL : ImClone Systems
		Bristol-Myers and ImClone said they are encouraged with the latest results and plan to discuss approval for Erbitux with Food and Drug Administration officials.
		ImClone and its anti-cancer drug have been at the center of controversy since late 2001 when the Food and Drug Administration refused to accept the marketing application for Erbitux, citing shoddy trials conducted by ImClone.
		Sam Waksal, ImClone's founder, was later accused of tipping off relatives about the FDA setback so that they could sell company stock before the news became public.
	www.suite101.com /discussion.cfm/investing/21616/802736 (672 words)

	ImClone.com Investor Relations - Press Release
		Data were presented from clinical studies exploring treatment of various stages of colorectal, head and neck, and ovarian cancers using ERBITUX either as a single agent or in combination with cytotoxic agents, including chemotherapy and radiation therapy.
		"Bristol-Myers Squibb and ImClone Systems are dedicated to the ongoing investigation of ERBITUX and to providing more treatment options for cancer patients in the future," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb.
		Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.
	phx.corporate-ir.net /phoenix.zhtml?c=97689&p=irol-newsArticle&ID=710071&highlight= (1465 words)

	ImClone Systems: Will It Benefit From a Dose of Carl Icahn? - SeekingAlpha
		When you offered me a directorship at ImClone in August, we discussed and I thought you indicated that you would not continue to be the Chairman of the Board of the Company.
		Fischer is still employed by ImClone on the date that bonuses for fiscal 2006 are paid, he will receive a bonus of no less than $500,000 and, if the Company employs him on December 31, 2007, he will receive a $500,000 retention bonus.
		During your tenure, ImClone hired a President and CEO who was totally the wrong person for the position and it took you many many months to recognize this and replace him.
	biotech.seekingalpha.com /article/17421 (2151 words)

	AVCG News: ImClone Systems Incorporated - The Oracle of Biotechnology...
		ImClone Systems, Inc. (Nasdaq:IMCL) has been suggesting higher long-term growth prospects based on solid fundamental indicators, and market technical analysis.
		ImClone said that because the study hadn't been designed to assess organ preservation, the results weren't statistically significant.
		On April 3 2006, Imclone Systems issued an approval of its drug Erbitex to the European Commission for the treatment of head and neck cancers.
	www.avcg.net /news/newsandarticles_article.asp?DID=103 (1634 words)

Try your search on: Qwika (all wikis)